Tebotelimab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tebotelimab, covering 2025-04-22 to 2025-04-22. Get the full timeline:
Most recent: Clinical Trial Update: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer [Phase 2, Phase 3]